Exploring the experience and challenges for PD STAT clinical trial participants: a qualitative study
Objective: This study aims to identify the reasons why people living with Parkinson’s disease (PD) (PwP) became involved with the PD STAT randomised controlled trial…Increasing chances of detecting a neuroprotective signal in PhI/II PD clinical trials?
Objective: Design an early CT program to detect a neuroprotective signal in PD. Background: Attempts to develop PD modifying therapies have been largely disappointing so…Utilization patterns of Amantadine in Parkinson’s Disease patients enrolled in the French COPARK study
Objective: To explore amantadine IR utilization patterns in the French COPARK study. Background: Immediate release (IR) amantadine is marketed for the treatment of early and…Yerba mate tea (Ilex paraguariensis) exerts a neuroprotective effect on intrastriatal 6-OHDA-lesioned mice model of Parkinson’s disease
Objective: We set to investigate the possible neuroprotective effect of yerba mate (YM) consumption on dopaminergic neurons in a mice model of Parkinson’s disease (PD). Background: The motor…Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.
Objective: We aim to determine in a cell model neuroprotective effects of targeting lipoxygenases (LOXs), central players in Ferroptosis, a novel regulated iron-dependent cell death…Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy
Objective: The objective of the present investigation was to develop Mucoadhesive sustained release floating tablets of Silymarin using natural polymers (Coccinia grandis and Rumex vasicarious)…Alleviation of Parkinson’s and Associated Depression using Silymarin in Rotenone induced Mice Model of Parkinson’s Disease
Objective: The present study was undertaken in order find out the possible neuroprotective and antidepressant potential of Silymarin. The neuroprotective and antidepressant potential was evaluated…The NIC-PD-study –A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson‘s disease in Germany and N. America
Objective: To evaluate the disease modifying potential of transdermal (TD) nicotine in early Parkinson’s disease (PD). For this explanatory purpose, the primary endpoint was the…What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years
Objective: To evaluate variation in Phase 2 and 3 Parkinson’s disease (PD) neuroprotective trial designs and identify key trial design features in Phase 2 studies…A first-in-human clinical study to test the safety and preliminary efficacy of CDNF in Parkinson’s disease
Objective: To develop a novel disease-modifying therapy in Parkinson's disease (PD) that affects both motor and non-motor symptoms, based on a novel stress-protective protein CDNF.…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 13
- Next Page »